Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of cinacalcet in pediatric dialysis patients with secondary hyperparathyroidism
2014-003563-38Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cinacalcet in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Amgen. Primary endpoint: Long-term safety and tolerability. Started Nov 2014; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2014-003563-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003563-38.